Literature DB >> 26432362

The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.

Adi Moseri1, Zohar Biron1, Boris Arshava2, Tali Scherf3, Fred Naider2, Jacob Anglister1.   

Abstract

The peptide T20, which corresponds to a sequence in the C-terminal segment of the HIV-1 transmembrane glycoprotein gp41, is a strong entry inhibitor of HIV-1. It has been assumed that T20 inhibits HIV-1 infection by binding to the trimer formed by the N-terminal helical region (HR1) of gp41, preventing the formation of a six helix bundle by the N- and C-terminal helical regions of gp41. In addition to binding to gp41, T20 was found to bind to gp120 of X4 viruses and this binding was suggested to be responsible for an alternative mechanism of HIV-1 inhibition by this peptide. In the present study, T20 also was found to bind R5 gp120. Using NMR spectroscopy, the segments of T20 that interact with both gp120 and a gp120/CD4M33 complex were mapped. A peptide corresponding to the fourth constant region of gp120, sC4, was found to partially recapitulate gp120 binding to T20 and the segment of this peptide interacting with T20 was mapped. The present study concludes that an amphiphilic helix on the T20 C-terminus binds through mostly hydrophobic interactions to a nonpolar gp120 surface formed primarily by the C4 region. The ten- to thousand-fold difference between the EC50 of T20 against viral fusion and the affinity of T20 to gp120 implies that binding to gp120 is not a major factor in T20 inhibition of HIV-1 fusion. Nevertheless, this hydrophobic gp120 surface could be a target for anti-HIV therapeutics.
© 2015 FEBS.

Entities:  

Keywords:  CCR5; HIV-1 inhibitors; NMR; T20; gp120

Mesh:

Substances:

Year:  2015        PMID: 26432362      PMCID: PMC4715528          DOI: 10.1111/febs.13541

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  35 in total

Review 1.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

2.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

3.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

Authors:  M K Lawless; S Barney; K I Guthrie; T B Bucy; S R Petteway; G Merutka
Journal:  Biochemistry       Date:  1996-10-22       Impact factor: 3.162

4.  Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

Authors:  Rosa M F Cardoso; Michael B Zwick; Robyn L Stanfield; Renate Kunert; James M Binley; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Immunity       Date:  2005-02       Impact factor: 31.745

5.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion.

Authors:  C Wild; T Greenwell; T Matthews
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

6.  Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.

Authors:  L T Rimsky; D C Shugars; T J Matthews
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.

Authors:  Shuwen Liu; Hong Lu; Jinkui Niu; Yujia Xu; Shuguang Wu; Shibo Jiang
Journal:  J Biol Chem       Date:  2005-01-07       Impact factor: 5.157

8.  An inducible HIV type 1 gp41 HR-2 peptide-binding site on HIV type 1 envelope gp120.

Authors:  S Munir Alam; Casey A Paleos; Hua-Xin Liao; Richard Scearce; James Robinson; Barton F Haynes
Journal:  AIDS Res Hum Retroviruses       Date:  2004-08       Impact factor: 2.205

9.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more
  2 in total

1.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

2.  Statistical correlation of nonconservative substitutions of HIV gp41 variable amino acid residues with the R5X4 HIV-1 phenotype.

Authors:  Elena Pacheco-Martínez; Evangelina Figueroa-Medina; Carlos Villarreal; Germinal Cocho; José L Medina-Franco; Oscar Méndez-Lucio; Leonor Huerta
Journal:  Virol J       Date:  2016-02-16       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.